^
Association details:
Biomarker:KIT mutation
Cancer:Melanoma
Drug:Opdivo (nivolumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

Excerpt:
A mutation, translocation, or fusion in the KIT gene in the patient's tumor felt to be potentially sensitive to tyrosine kinase inhibition.
Trial ID: